Inflammatory Mediators and Cytokines involved in Rheumatoid Arthritis

- Authors: Vikash Sharma1, Shiv Shankar Shukla2, Amber Vyas3, Ravindra Kumar Pandey4
-
View Affiliations Hide AffiliationsAffiliations: 1 Department of Pharmacology, Anand College of Pharmacy, Agra (U.P.), India 2 Department of Pharmaceutical Analysis and Quality Assurance, Columbia Institute of Pharmacy, Raipur (C.G.), India 3 Department of Pharmacy, University Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur (C.G.), India 4 Department of Pharmacognosy, Columbia Institute of Pharmacy, Raipur (C.G.), India
- Source: Natural Products for the Management of Arthritic Disorders , pp 118-134
- Publication Date: August 2022
- Language: English
nbsp;Rheumatoid arthritis (RA) is a chronic inflammatory disease that mostly affects the joints. Inflammation is an immune response of the human body, but an overabundance of such responses is thought to be a key element in the evolution of many other issues, including RA, cancer, and neurological illnesses. The growth and inhibition of RA necessitate the identification of a precise mechanism and target in the body. Interleukins (IL), tumour necrosis factors (TNF-), interferons (INF), and arachidonic acid derivatives are the most important cytokines and inflammatory mediators in rheumatoid arthritis. IL-6 inhibitors, JAK inhibitors, anti-TNF, and currently available disease-modifying anti-rheumatic medications (DMARDs) have all been demonstrated to be effective in the treatment of RA. We have also summarised the inflammatory mediators such as arachidonic acid metabolites and their role in inflammation. This chapter also observed cytokines and other transcription factors that play a role in the disease's onset and progression. The current study includes a wide range of issues, including RA molecular pharmacology, such as cytokines pharmacology, transcription factors, and other active biomolecules. However, the study shows that a number of biomolecules and mediators play a key role in the pathogenesis of RA, and a thorough understanding of the underlying pathways can aid in the creation of new targeted pharmacological therapies that are both safer and more effective in RA.
-
From This Site
/content/books/9789815050776.chap6dcterms_subject,pub_keyword-contentType:Journal105
